Key Highlights

  • The all‑stock merger provides a concurrent $320 million financing package to support AVR‑001 through Phase 2b and the start of a Phase 3 psoriasis trial.
  • A private placement of $251 million in convertible notes will be exchanged for common stock at merger closing.
  • Hansoh secures exclusive rights outside China with an upfront $120 million payment and potential milestone earnings up to $2.18 billion.

The definitive merger between NextCure, Inc. And Avere Therapeutics, Inc. Creates a new entity, Avere Therapeutics, Inc. Trading under the ticker AVRX. The transaction delivers a $320 million cash infusion, positioning the combined company to advance its once‑weekly oral IL‑23 antagonist, AVR‑001, through late‑stage clinical development.

What Happened

NextCure and Avere signed a definitive all‑stock agreement that will close in the second half of 2026. Under the terms, NextCure shareholders will receive roughly 1.21% of the post‑merger equity, while Avere shareholders will own about 98.79%. Andrew Cheng, MD, PhD, will serve as chief executive, president and chairman of the new company, supported by a management team that includes Kitty Yale and William White.

A contingent value right grants NextCure investors 90% of net proceeds from any license, divestiture or monetization of NextCure pipeline assets for two years after closing.

Market Impact

The infusion of $320 million, supplemented by a $251 million convertible note private placement, is expected to fund activities up to the readout of a global Phase 2b study and support a Phase 3 psoriasis trial. The financing strengthens the biotech sector’s pipeline funding outlook and may influence capital allocation decisions among venture investors focused on immunology. The deal also secures exclusive ex‑China rights for AVR‑001, with Hansoh receiving an upfront $120 million and the opportunity to earn up to $2.18 billion in development and sales milestones, plus mid‑single‑ to low‑double‑digit royalties.

These terms underline the growing appetite for oral biologics within the pharmaceutical supply chain.

What’s Next

A Phase 1b study conducted by Hansoh reported early efficacy signals and a favorable safety profile for the oral cyclic peptide IL‑23 receptor antagonist. The United States IND for AVR‑001 remains active, with the initiation of a Phase 2b trial slated for early 2027 and a readout anticipated in the first half of 2028. In China, a Phase 2b psoriasis trial is expected to deliver results in 2027.

The combined company will focus on advancing AVR‑001 through these milestones while evaluating additional partnership opportunities.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.